Oestrogen Medicament with Cyclodextrin for Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound healing therapies are inadequate in accelerating the healing of skin wounds, often resulting in prolonged healing times, increased infection risk, and undesirable tissue regeneration, with existing medicaments exhibiting variable efficacy and potential adverse effects.
Innovation Solution
The use of an oestrogen-based medicament in an injectable carrier solution comprising an alcohol and a phosphate buffer, specifically 17β-oestradiol, is proposed to accelerate wound healing by enhancing re-epithelialization and tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional wound healing therapies are used, then wound healing occurs naturally, but healing time is prolonged and efficacy is variable
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition parameters of the wound treatment formulation. Specifically, it uses a defined ratio of cyclodextrin (2:1 alpha-cyclodextrin to gamma-cyclodextrin) combined with specific concentrations of oestrogen (0.01-1% w/v) to accelerate wound healing. This systematic adjustment of compositional parameters resolves the contradiction by achieving faster healing rates while maintaining consistent efficacy.
Solution Approach 2:
The patent employs composite materials by combining cyclodextrins with oestrogen in a specific formulation. The cyclodextrin complexing agent enhances the solubility and delivery of oestrogen to the wound site, creating a synergistic composite material that accelerates healing more effectively than either component alone, thereby improving productivity while reducing healing time.
2Productivity
If existing medicaments are used to accelerate wound healing, then healing speed increases, but adverse effects and infection risk increase
Solution Approach 1:
The patent uses cyclodextrin as an intermediary substance that complexes with oestrogen to enhance its delivery and efficacy. This intermediary approach allows the use of lower concentrations of oestrogen (0.01-1% w/v) while achieving accelerated healing, thereby reducing adverse effects and infection risk associated with higher concentrations or alternative medicaments.
Solution Approach 2:
The patent optimizes the concentration parameter of oestrogen to a specific range (0.01-1% w/v) that balances healing acceleration with safety. This parameter optimization ensures therapeutic efficacy while minimizing harmful effects, resolving the contradiction between improved healing rate and reduced infection risk.
3Productivity
If surgical excision is used to clear wound area, then non-viable tissue is removed rapidly, but pain increases and complications arise from increased injury
Solution Approach 1:
The patent employs a topical medicament formulation that can be applied directly to the wound site and allows for easy removal or replacement. This disposable-like approach avoids the need for invasive surgical excision, achieving effective tissue clearance without the pain and complications associated with surgical intervention.
Solution Approach 2:
The cyclodextrin-oestrogen formulation acts as an intermediary therapeutic agent that promotes natural tissue clearance and healing processes. This mediates the tissue clearance function, achieving effective removal of non-viable tissue through biochemical rather than mechanical means, thereby avoiding pain and surgical complications.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides a compound that promotes oestrogenic activity for use as a medicament, wherein the medicament comprises said compound provided in an injectable carrier solution, the injectable carrier solution comprising an alcohol and a phosphate buffer. Such a medicament may provide between 0.005 μg and 4μg of the compound that promotes oestrogenic activity per wound centimetre. The concentration of phosphate may be between 1 mM and 50 mM. The concentration of the alcohol may be between 0.17 M and 1.71 M. The medicaments of the invention may be provided at a wound site for the acceleration of wound healing.